These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 11822766)

  • 1. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors.
    Marty M; Fumoleau P; Adenis A; Rousseau Y; Merrouche Y; Robinet G; Senac I; Puozzo C
    Ann Oncol; 2001 Nov; 12(11):1643-9. PubMed ID: 11822766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral versus intravenous vinorelbine: clinical safety profile.
    Gebbia V; Puozzo C
    Expert Opin Drug Saf; 2005 Sep; 4(5):915-28. PubMed ID: 16111453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors.
    Rowinsky EK; Noe DA; Trump DL; Winer EP; Lucas VS; Wargin WA; Hohneker JA; Lubejko B; Sartorius SE; Ettinger DS
    J Clin Oncol; 1994 Sep; 12(9):1754-63. PubMed ID: 8083697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of food and divided dosing on the bioavailability of oral vinorelbine.
    Rowinsky EK; Lucas VS; Hsieh AL; Wargin WA; Hohneker JA; Lubejko B; Sartorius SE; Donehower RC
    Cancer Chemother Pharmacol; 1996; 39(1-2):9-16. PubMed ID: 8995494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours.
    Bourgeois H; Vermorken J; Dark G; Jones A; Fumoleau P; Stupp R; Tourani J; Brain E; Nguyen L; Lefresne F; Puozzo C
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):407-13. PubMed ID: 17541591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine.
    Variol P; Nguyen L; Tranchand B; Puozzo C
    Eur J Clin Pharmacol; 2002 Oct; 58(7):467-76. PubMed ID: 12389069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The absolute bioavailability of oral vinorelbine in patients with solid tumors.
    Lush RM; McCune JS; Tetteh L; Thompson JA; Mahany JJ; Garland L; Suttle AB; Sullivan DM
    Cancer Chemother Pharmacol; 2005 Dec; 56(6):578-84. PubMed ID: 16001165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC).
    Bonneterre J; Chevalier B; Focan C; Mauriac L; Piccart M
    Ann Oncol; 2001 Dec; 12(12):1683-91. PubMed ID: 11843245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vinflunine oral pharmacokinetics and absolute bioavailability of soft and hard gelatin capsules: results of two phase I trials.
    Delord JP; Bennouna J; Mourey L; Bougaret J; Brandely-Talbot M; Ferré P
    Clin Pharmacokinet; 2012 Jun; 51(6):357-64. PubMed ID: 22471295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma].
    Bartsch V
    Onkologie; 2006 Mar; 29 Suppl 1():1-28. PubMed ID: 16534241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood and plasma pharmacokinetics of vinorelbine in elderly patients with advanced metastatic cancer.
    Gauvin A; Pinguet F; Culine S; Astre C; Cupissol D; Bressolle F
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):48-56. PubMed ID: 11855752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of vinorelbine.
    Levêque D; Jehl F
    Clin Pharmacokinet; 1996 Sep; 31(3):184-97. PubMed ID: 8877249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients.
    Loos WJ; de Wit R; Freedman SJ; Van Dyck K; Gambale JJ; Li S; Murphy GM; van Noort C; de Bruijn P; Verweij J
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):407-12. PubMed ID: 17051369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: results of a pharmacokinetic study.
    Kitzen JJ; Puozzo C; de Jonge MJ; Brandely M; Verweij J
    Eur J Cancer; 2010 Jan; 46(2):266-9. PubMed ID: 19944596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of food on the pharmacokinetic profile of oral vinorelbine.
    Bugat R; Variol P; Roché H; Fumoleau P; Robinet G; Senac I
    Cancer Chemother Pharmacol; 2002 Oct; 50(4):285-90. PubMed ID: 12357302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-small-cell lung cancer in elderly patients: influence of age on vinorelbine oral pharmacokinetics.
    Puozzo C; Gridelli C
    Clin Lung Cancer; 2004 Jan; 5(4):237-42. PubMed ID: 14967076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients.
    Jassem J; Ramlau R; Karnicka-Młodkowska H; Krawczyk K; Krzakowski M; Zatloukal P; Lemarié E; Hartmann W; Novakova L; O'Brien M; Depierr A
    Ann Oncol; 2001 Oct; 12(10):1375-81. PubMed ID: 11762807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group.
    Johansen M; Kuttesch J; Bleyer WA; Krailo M; Ames M; Madden T
    Clin Cancer Res; 2006 Jan; 12(2):516-22. PubMed ID: 16428494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral vinorelbine: feasibility and safety profile.
    Depierre A; Freyer G; Jassem J; Orfeuvre H; Ramlau R; Lemarie E; Koralewski P; Mauriac L; Breton JL; Delozier T; Trillet-Lenoir V
    Ann Oncol; 2001 Dec; 12(12):1677-81. PubMed ID: 11843244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.